Pod Insights Pharmacy Podcast Network The Mythbusting Episode | Essential: Pharmacy Compounding Podcast APC About this episode In this edition of Essential, we’ve got updates on some big compounding news — like the FDA’s long-overdue decision to remove the boxed warning from some menopause hormone-replacement therapy drugs. (And yes, that’s important for compounding pharmacists!)We also look at the hubbub at FDA over what (allegedly) was behind the decision that would have effectively banned compounding with desiccated thyroid extract, plus some stories from the states, and more. This month’s deep dive: Mythbusting, compounded-GLP-1 style! What have the big drugmakers been saying, and how much of it is true? They’re spreading stories, but our experts put them to the test. Don’t miss out! LinksJoin APC today: https://a4pc.org/membership FDA to remove boxed warning from HRT medications: https://archive.ph/R8DJD An example of what appears to be an op-ed pushed by a pharma company. The writer, a “former healthcare professional,”doesn’t appear to exist: https://archive.ph/OPNWr Find a legitimate, licensed compounding pharmacy: https://a4pc.org/isitlegit Benefits of becoming an APC PFM: https://a4pc.org/pfm
Transcript 0:05 Speaker 00 You are listening to the global network of podcasters dedicated to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
0:25 Speaker 01 Welcome back to Essential, the pharmacy compounding podcast with the latest news and analysis from, you know it, the Alliance for Pharmacy Compounding, the voice for compounding pharmacy. I'm your host, Andrew Cantor, and after the news, we've got APC's Scott Bruner and Tenille Davis to do some serious myth busting of what's being said about compounding these days. But before we get to the news, I've got a little bit of bragging to do. As of this week, APC's membership has topped 7,000 compounding professionals for the first time, like ever. The actual number as of last week was 7,437.
1:07 Speaker 01 That's almost 7,500 pharmacy compounding professionals who are putting their confidence in us and what we're doing to protect pharmacy compounding. We cannot thank them enough. And if you are involved in pharmacy compounding and you aren't an APC member, reexamine your life choices and join us. All right, now we can do the news.
1:38 Speaker 01 It took long enough, but the FDA announced that it's finally removing the infamous boxed warning from hormone replacement therapy products. And I say infamous because, all right, I won't go into the nitty gritty of why the warning was problematic. Let's just say it was based on a single study with some remarkably faulty conclusions. The FDA's decision is a big deal for patients and prescribers, for sure. Hopefully, it'll dial back the whole fear factor that's still lingering over hormone therapy. But this is a compounding pharmacy podcast. So what, you may ask, does this announcement mean for compounded hormones? Remember, compounding pharmacies, they can't make claims about the drugs they prepare, not efficacy, not adverse events.
2:22 Speaker 01 So that black box warning, it didn't apply to compounded hormone therapy. But the FDA's announcement is potentially good news for compounding, simply because it's hopefully a signal that the agency is going to be relying more on better science when it makes its decisions. Like I said, the warning on hormone replacement therapy, it was based on a single flawed study, and it took years after newer, better studies came out before the agency removed that warning. Well, there's another old and flawed study out there. This one was commissioned by the FDA back in 2019, and that one is about compounded hormone replacement therapy. It was done by the National Academies of Science, Engineering, and Medicine,
3:06 Speaker 01 NASM, and you would think that makes it pretty objective, but it wasn't. To make a long story short, it had a lot of political fingerprints on it, a bit of meddling. Thankfully, the FDA hasn't used that NASM study to make any decisions about compounded hormones, but it had been dropping some hints that it might. And that's something APC has been pushing back on for years. So seeing that the agency might actually look at objective science, at least when it comes to hormone therapy, sorry, Tylenol, that's potentially really good news. It's not an exaggeration to say that compounded hormone therapy is life-changing stuff. So if you're going to meddle with it, you're going to regulate it, you really need to have science behind you.
3:50 Speaker 01 There was one comment in the press conference that caught our attention. When a reporter asked the FDA commissioner how the hormone decision might apply to compounding, he was pretty clear they didn't want the government to come between patients and their healthcare professionals. Here's a clip.
4:04 Speaker 02 I just remembered you asked about compounding, and I didn't answer that question. So there are legal criteria for compounding, and we're going to continue to respect those boundaries. Thank you.
4:14 Speaker 01 So yeah, we're feeling cautiously optimistic about how this might play out on the compounding front.
4:24 Speaker 01 So by now, there's no way you haven't heard about what happened at FDA with Dr. George Tidmarsh, the guy who had been head of the agency's drug division. Apparently, or rather allegedly, based on some of Tidmarsh's LinkedIn posts, it kind of came out that he was pushing the FDA to make decisions so he could settle some personal scores, allegedly. One of those scores happened to be allegedly against the head of a company that makes a thyroid extract. And that allegedly is why the agency, pretty much out of the blue and without any science, suddenly decided a couple of months ago that it was going to stop companies and compounders
5:04 Speaker 01 from using some natural thyroid products in drugs, including desiccated thyroid extract, DTE. So all this time, we thought the FDA's decision was pretty weird. It came out of nowhere. It didn't make any scientific sense, and it even went against the agency's own policies. If nothing else, we've never heard of the FDA declaring that a drug is a biologic based on an inactive ingredient, as it has with DTE. So would that mean any drug that uses, say, a gelatin capsule was a biologic? The point is, it was just weird. And now we may know why the whole Tidmarsh drama explains a lot, allegedly. And that's why APC just about immediately sent a letter to the FDA demanding that it
5:47 Speaker 01 reverse its decisions, decisions plural, both the reclassification of DTE as a biologic and the overall ban on natural thyroid products, now that we know there was this whole personal vendetta thing going on, allegedly. Oh, and what's also interesting, and kind of hanging over this whole debacle, is that it sure does seem it was awfully easy for a single person to change a pretty big FDA policy. It doesn't strike us as the right way to run a federal agency, especially one that's supposed to be protecting folks' health. So tune in tomorrow for the next episode of As the FDA Turns. Now, how about Days of FDA?
6:28 Speaker 01 Anyway, oh, by the way, if you want to help keep up the pressure on the FDA over the ban on DTE, you'll find a couple of links in the show notes to our tools that make it easy. Onward.
6:41 Speaker 01 Okay, this is not legal advice. We're not lawyers. This is just a podcast. That said, in the name of all that's holy, don't compound with retra trutide or cagrelentide. Yes, we know that legitimate pharmacies aren't usually the ones doing this. It's med spas and companies posing as pharmacies that are. But we want to head off even the hint of temptation. So let me say once more with feeling, there is no wiggle room here. There's no loophole. The FDA has been crystal clear. Retra trutide and cagrelentide are not components of any FDA approved drug. They don't have monographs. They're not on the 503A bulks list, which means you cannot legally compound with them. Full stop.
7:26 Speaker 01 Yes, yes, yes, there's a lot of interest in peptides like those. And yes, there are those illegal pop-up shops claiming to sell one or the other. Whoop-de-doo, it's not legal. Don't do it. Oh, and while we're ranting, don't compound with research-grade API either. But you knew that already, right?
7:45 Speaker 01 There've been a few interesting compounding-related things going on at the state level that caught our attention. Like in Rhode Island, the board of pharmacy there is updating the compounding regulations. One of the things we do here is take a look at stuff like that, just in case. And it's a good thing because it seems that the new regs being proposed in Rhode Island would blur the line between routine IV preparation and complex compounding. That is a recipe for confusion and could even mean some pharmacists being out of compliance, even with the best of intentions. Yes, yes, APC will be commenting. And in Maryland, there's a new law that requires every pharmacy licensed in the state
8:27 Speaker 01 to submit dispensing data on non-controlled substances to the state's health information exchange. Now, that's not a big deal. The problem is that Maryland hasn't done a very good job of communicating the new requirement to pharmacies. It's actually been three years since the law was passed, but there's been virtually nothing in any state materials. So a lot of pharmacists feel like they're being blindsided by a pretty major rule that feels like it came out of nowhere. As we wrote to the Maryland Board, what we have here is a failure to communicate. And we hope it'll fix that before it starts enforcing the law. And then there's Texas. The board there is working through updates to its sterile compounding rules. But some of the proposed language, let's just say, it creates a bit
9:12 Speaker 01 of uncertainty about what requires sterility testing, the timing of those tests, and how batch size applies. It's a solid draft, for sure, but we think it needs a bit more refinement, so we end up with clearer directions for pharmacies. Now, look, this is a shameless plug. These kinds of state boards, we'll call them stumbles. They happen a lot. APC keeps on top of it all, and we advise these state boards with comment letters. We actually have a weekly report about all of what's happening in the states, but you can only get it if you're a pharmacy facility member of APC, a PFM. And there's a link to becoming a PFM in the show notes. All right, and now it's time for this episode's deep dive.
9:57 Speaker 01 At least since the beginning of the GLP-1 craze, and then the GLP-1 shortages, drugmakers have been working pretty hard to attack pharmacy compounding any way they can. We've reached kind of a surreal point where giant multinational corporations are deliberately, I can't say lying, because it gets lawyers upset, they're deliberately spreading misinformation about compounded drugs and about compounding pharmacists, and it's all to scare regulators and the public and drive their own businesses. And they're doing it big time. Opinion pieces, letters to the editor from people claiming to be independent, letters full of misinformation to pharmacies, to boards of pharmacy. They're filing nuisance lawsuits that they just keep
10:40 Speaker 01 losing. It's actually gotten to the point of absurdity. These companies are even creating fake organizations with real sounding names, like, I don't know, the American Alliance for Obesity and Freedom in Apple Pie. Then someone submits an op-ed to a local paper using that fake organization as a credential. One we looked into miraculously sprang into existence this past March. But editors, they don't have time to check on every one of them. So yeah, drug makers are trying to wage a war of misinformation on as many fronts as possible. So let's go through some of what these companies have been saying lately. Joining me today to do a bit of myth busting are APC Mythbuster in Chief Scott Bruner
11:24 Speaker 01 and his sidekick, Chief Advocacy Officer Tenille Davis, who also happens to be a practicing pharmacist. Welcome, guys. Okay, let's tackle one of the biggest talking points first. According to what the big drug makers are saying, since the FDA resolved GLP-1 shortages, it's actually illegal for pharmacists to compound them? Is that true?
11:45 Speaker 03 Nonsense. It's not illegal to compound GLP-1s. Remember that compounding is authorized in a couple of circumstances. Compounders can prepare copies of FDA-approved drugs when the drugs are listed as currently in shortage on FDA's Drug Shortage List. GLP-1s are now out of shortage. But the other condition in which compounding is authorized is when a prescriber judges that a custom formulation is needed for an individual patient. Prescribers continue to write for those custom formulations of GLP-1s as allowed, authorized in the Food, Drug and Cosmetic Act. Compounding pharmacies are filling those prescriptions. Drug makers have indeed made that statement in letters and appearances before state boards
12:29 Speaker 03 of pharmacy, in communication with members of Congress and other regulators. It's just not true.
12:36 Speaker 01 And to be clear, you said that it's a prescriber who decides if a patient needs a compounded version of the drug. So it's not like pharmacy can decide, "Oh, I'm not going to give you the brand name, the FDA-approved drug, I'm going to give you a compounded version instead."
12:52 Speaker 03 No, you're exactly right. The prescriber judges when a compounded drug is prescribed. It's not like she writes Wegovy on the prescription and the patient hops down to the pharmacy and the pharmacist says, "Oh, I don't have any of that, I'm just going to compound it." No, the prescriber has to write for a compounded drug. So they're not writing for Wegovy, they're writing for compounded semaglutide injection. Again... Custom formulations are allowed now. Copies of FDA-approved drugs are not.
13:22 Speaker 01 Okay, so copies are not allowed. How about this one that also comes up a lot? These compounded versions of FDA-approved drugs. They are not safe because, as the name implies, they aren't actually FDA-approved. So is that true? If they're not approved, then how can people be sure they're safe?
13:42 Speaker 04 You're absolutely right. Compounded medications are not FDA-approved. But that doesn't mean that they are inherently unsafe, just as FDA approval doesn't guarantee safety. We know that there's been drugs that have been taken off the market that had previously obtained FDA approval in the past. Compounded medications can't be FDA-approved. They're intended to be custom-formulated for an individual patient based on a specific prescriber's order. To get FDA approval, drug companies have to go through double-blind placebo-controlled trials and submit all sorts of data to the FDA that is impractical to do with a medication that is intended for an N of 1 or an individual patient.
14:26 Speaker 03 Yeah, and the other thing I would say about that is FDA-approved drugs are adherent to current good manufacturing practices for a reason. They are mass-produced. This is a drug made for millions. Compounded drugs, as Tenille said, are made for an N of 1, for an individual patient. These are not drugs to be mass-produced for millions of patients. And so the framework, the compliance framework, the safety framework, the regulatory framework in which these drugs are prepared are appropriate for a medication made for an individual patient.
15:00 Speaker 04 Yeah, FDA-approved drugs are always the first choice. First-line therapy should be an FDA-approved product. And it's only in situations where the FDA-approved drug is in shortage or not appropriate for a patient because they need some sort of customized dosage form, strength that doesn't exist, combination product, preservative-free version, whatever the prescriber determines that patient might need. Those are only appropriate if the FDA-approved product is, you know, not appropriate for the patient instead.
15:32 Speaker 01 So you've got all these versions of compounded drugs, like you said, they're with different dosages amounts or potentially with various other drugs mixed in as is needed by a particular patient. Okay, that makes sense. But, I mean, when it comes down to it, are these compounded drugs, I know you don't like the term, but they're knockoffs, right? I mean, they're not the same as, as the FDA-approved version. They're, they're, all right, it's a bad word, but they're fakes, right? They're not the real thing?
16:03 Speaker 03 No, no, no, that's nonsense as well. FDA calls these essentially copies of FDA-approved drugs, or custom formulations. And indeed, FDA never refers to them as copycats, or knockoffs, or any of the pejoratives that we hear reporters from time to time use in their news stories. These aren't handbags laid out on some Manhattan sidewalk somewhere. These are custom medications, made in USP-compliant compounding laboratories by licensed pharmacists and technicians. And FDA says, provided they are made with the active pharmaceutical ingredient that
16:46 Speaker 03 comes from an FDA-registered facility, and that's the same as the API in the FDA-approved drug. They are absolutely compliant, absolutely legal, and absolutely appropriate when a prescriber judges that an individual patient needs that drug.
17:02 Speaker 01 But here's something that confuses me then. Okay, so, so the active ingredients, you're saying it's the same, but when GLP-1s were in shortage, if these same ingredients were available for compounding pharmacists, then why were they in shortage?
17:20 Speaker 03 Well, there is a bit of confusion about how that works. First of all, FDA does not approve API, and the FDA drug shortage list does not list APIs. It lists shortages of FDA-approved drugs. And so during the entire shortage of semaglutide, the Novo Nordisk
17:42 Speaker 03 Product and terzepatide, the Eli Lilly product, never once was the active pharmaceutical ingredient in shortage. And we know that because, for instance, with semaglutide, there was never a shortage of ribelsis, the oral version of semaglutide. No, what was in shortage was the FDA-approved drug. And again, it's hearsay. I don't know that we know, but something in the production process was the holdup, and that's what led the drug to be in shortage, not the lack of the API.
18:20 Speaker 03 Compounding pharmacists were acquiring API from FDA-registered and, as it turns out, FDA-inspected and CGMP-compliant manufacturers, many of those in China. But FDA recently released a green list validating that those manufacturers were CGMP-compliant, had been inspected by FDA. And so they're using API that FDA seems to have no qualms with. Not once in this GLP-1 frenzy and the entry of compounding into the GLP-1 market has FDA raised a single point of concern about the quality of the active pharmaceutical ingredient.
19:04 Speaker 01 I think you actually headed off my next question, which was, we hear a lot that the API that compounding pharmacists are using come from overseas. They come from foreign countries, places like China and India that I guess we can't trust. I mean, are the big drug makers getting their ingredients from good old American sources? I mean, how does that work? Why are these companies pushing the fact that compounders are getting their ingredients overseas?
19:39 Speaker 04 I think that it's a misunderstanding as to how a typical compounding pharmacy acquires active pharmaceutical ingredients or API. So, most independent, you know, state licensed legitimate compounding pharmacies are getting active pharmaceutical ingredients from FDA-registered wholesalers. Those FDA-registered wholesalers in turn purchase API from FDA-registered manufacturers. Many of these wholesalers conduct third-party testing on the API that they bring in to sell to independent pharmacies. So pharmacies are not calling up China and ordering API to be delivered to their doorstep.
20:18 Speaker 04 Is there a lot of research-grade, you know, peptide drugs being sold online without a prescription? Uh, yes, but that's not compounding and it's not pharmacy. So when we're talking about that sort of API, you know, importation into the United States, that's not going to legitimate state-licensed compounding pharmacies. And it's underscored by what Scott was talking about with the, with the Green List. So FDA came out with a list of manufacturers that it deems to be in compliance with FDA standards for manufacturing GLP-1s. The existence of that list underscores the fact that FDA does think that there are manufacturers
21:00 Speaker 04 beyond the drug makers that are making appropriately graded API.
21:06 Speaker 03 Yeah, and I want to, I, I do want to add on, one of the, the, the groups fronted, funded, I guess, by the drug makers, has begun to release a report with some regularity about illicit substances that have been intercepted, illicit API that have been intercepted at the US border. There is no doubt that there is a gray market and there is a market for illicit substances and those substances are coming into the country and they may or may not be what they purport to be. This group has asserted that because some of them have been cleverly marked for use in pharmacy compounding, that as Tenille mentioned...
21:49 Speaker 03 But they must have been ordered by a state licensed compounding pharmacy and were somehow making their way into drugs prepared for patients. There's not a shred of evidence that that has happened. And as Tenille said, it misunderstands how the supply chain works. And yet, there is this gray market, this black market, these substances that can't be relied upon. And Americans need to take care that they are getting compounded drugs from state licensed compounding pharmacies and not from some address that they found on a Reddit thread or some chat room online because their health could very well be at risk.
22:33 Speaker 01 Are you saying that they can't trust influencers on TikTok when someone recommends whatever, whatever, whatever dot com to get their discount semaglutide?
22:44 Speaker 03 Well, I don't know that you can throw every influencer under the bus, but there are many of them with dubious credentials at best. I would suggest that for your healthcare advice, you ought to go to a prescriber, a doctor, a nurse practitioner, PA, or your local pharmacist and maybe not rely on something you read on the internet.
23:04 Speaker 01 I want to get back for a second to the ingredients. So the ingredients, the APIs that legitimate state licensed compounding pharmacies are using, and we're going to use that phrase a bunch, they are safe. Okay, that's a given. But something I read, at least one company, and we'll just say it starts with an N and ends with OVO Nordisk, it says that its semaglutide API is better than what compounding pharmacists get because its recombinant, while the API compounders use is synthetic. I mean, is that a legitimate
23:44 Speaker 01 complaint that the version that compounding pharmacists are using is different because it's synthetic?
23:51 Speaker 04 So Novo Nordisk is correct. They do manufacture semaglutide via recombinant technology, whereas most API that is semaglutide in the marketplace is manufactured via synthetic technology. You know, conversely, Alter Zepatide is manufactured by a synthetic technology. So the other big drug maker isn't making this argument because their API is also manufactured via synthetic technology.
24:19 Speaker 04 They are different manufacturing processes, for sure, but the FDA, when a drug is allowed to become a generic for a medication that is manufactured via recombinant technology, it allows that generic manufacturer to use either recombinant or synthetic manufacturing for its approval, as long as it can prove that the API is the same at the end, so that the amino acid chain is the same as the recombinantly produced product. So their argument that the API is inherently different is not necessarily true, but it is true that they're manufactured using different technology.
25:00 Speaker 01 Tanil, you're saying FDA doesn't necessarily draw a distinction between recombinant and synthetic?
25:08 Speaker 04 Yes, they don't draw a distinction, as long as that the company that's applying for the generic, the new drug application, can prove that the API is the same. The outcome is the same.
25:20 Speaker 01 All right, so I'll accept that the pharmacies, they're safe, the drugs are good, they work, the whole process is safe, but what about when these compounded medications get into patients' hands? Hasn't there been like a lot of problems with patients mistosing themselves, what the FDA calls adverse events?
25:42 Speaker 04 So I'm gonna jump in and just clarify the definition of the word "safe" where it comes to compounding pharmacies and FDA-approved drugs. Compounded drugs and API can't be technically called "safe" by a compounding pharmacy, because terms like "safe" and "effective" have a legal definition that is associated with full FDA approval. Since compounded drugs are not FDA-approved, compounding pharmacies are not allowed to call them "safe" or "effective." Same with API. API is not FDA-approved, only finished dosage forms are, and so it can't be called "safe" by a compounding pharmacy.
26:21 Speaker 01 Ah, okay.
26:22 Speaker 04 But as far as the administration dosing errors, so most compounding pharmacies
26:28 Speaker 04 are dispensing these compounded GLP-1 drugs in a traditional vial and syringe system, just like insulin has been dispensed for years and many other injectable medications. The pen devices that the brand name drug manufacturers sure seem convenient for sure, but as long as the patient has adequate counseling, written directions, and ability to call a pharmacist or a prescriber with questions, they should reasonably be able to draw up the proper doses. I always recommend, if you are confused about what dose you need to inject, don't go to Instagram to ask the question about how much to draw up on your syringe. Call a pharmacist.
27:10 Speaker 04 If you're getting a medication from a legitimate state licensed pharmacist, they are available to you to answer any questions if you're confused.
27:19 Speaker 03 And Tanille, I'm trying to remember back. So FDA, a while back, I'm sorry, the months run together, but FDA did release an alert raising concerns about dosing errors. And I don't think anything in that alert, if I remember correctly, cast doubt about the quality of the compounded drug. It was really, as you say, about some vial and syringe dosing errors or some mistaken, I guess, dosage instructions, dosing instructions from the prescriber himself, herself. Am I getting that right?
28:02 Speaker 04 Yeah, you are. They did release a statement about dosing and administration errors and adverse events associated with those. And they focused on several things, but including prescribers that were escalating doses too fast or starting doses too high, those kind of things. So it's not just about the delivery device. It's about, you know, people maybe making a patient's dose go too high, too fast, and them having some adverse events.
28:32 Speaker 03 Andrew, I do want to raise a myth of my own to bust, and it has to do with adverse events reporting in general, not only for compounded drugs, but for FDA-approved drugs as well. FDA has an adverse events reporting system, a website. Anybody at all can report an adverse event. It doesn't have to be serious. In many instances, in fact, a multitude of adverse events reports are not themselves adverse events, but are side effects, known side effects of drugs. FDA does not investigate these.
29:12 Speaker 03 So you have a scenario where anybody can report anything they want, and it's not documented, investigated by FDA. And yet, we're seeing again and again, drug makers and others rely on data from that adverse events reporting system to suggest that somehow compounded drugs are less safe than the FDA-approved versions. I would suggest to you that that adverse events system does not demonstrate that. And indeed, FDA, in raising concerns about adverse events, has indicated that these are not investigated, these are simply reported.
29:52 Speaker 01 So if these companies, I want to go back to something we talked about earlier. If these companies are sending or encouraging people to send, for want of a better word, sham letters to editors of newspapers, they're making presentations for boards of pharmacy with misinformation, does it follow that some of these adverse events reports might be encouraged by drug makers? I mean, there's really no way to tell what is a legitimate report and what is just a side effect or user error?
30:29 Speaker 03 Well, to use a Shakespearean phrase, if they're doing that, they're hoists with their own petard because the same conditions apply to adverse events reported about the FDA-approved drugs. And there are exponentially more adverse events reports related to the FDA-approved GLP-1s. Now, drug makers, regulators, and others will reply, "Oh, but compounding pharmacies don't have to report adverse events." And that is absolutely true. But if there is a serious adverse event that causes patient harm, I can guarantee you that the prescriber, or the state board of pharmacy, or the family of the patient are absolutely
31:11 Speaker 03 going to report that to the FDA adverse events reporting system. And generally speaking, a pharmacy will as well, even though they may not be required to do it. Again, I'm talking about serious adverse events. I'm not talking about, "Oh, I got the injection and I felt nauseous." Well, I'm sorry, that's a known side effect of the drug. It's not an adverse event.
31:35 Speaker 01 But when you are counting the number of adverse events, that might actually get counted and tallied as one and held against a pharmacy?
31:46 Speaker 03 Could be.
31:47 Speaker 01 Okay, held against the compounded version. Okay, well, that honestly doesn't make much sense, but that's FDA policy. All right. One, I guess this is a kind of a different angle, a different myth that has come up, and I hope it's a myth. So let's assume, and I totally believe you, that the pharmacy is legit, the compounded versions of drugs are on par, shall we say, with commercial FDA-approved versions. But one thing the drug makers have been saying is that it's fine, yes, the law allows a compounded version of a drug for a specific patient, but...
32:30 Speaker 01 There are compounding pharmacies that are going way beyond what the law intended, and that they're saying the meds are personalized, but they're conveniently the same personalization for just about every patient. So they're essentially bulk compounding under the guise of personalization. Is this, is this something that's actually happening?
32:51 Speaker 03 Well, in a, in a lawsuit, they've actually used the expression sham personalization. Look, nothing happens in a compounding pharmacy until a prescription comes in. The prescriber has to judge that an individual patient merits a particular formulation before the compounding pharmacy can prepare that drug. Now, there was a lawsuit that was thrown out against, I'm trying to remember which one, I think it's Well Health, a few weeks ago, in which the judge indicated that just because something was made in some volume did not mean it was
33:33 Speaker 03 not patient-specific. And indeed, when I talk to compounding pharmacy owners, they, they, they tell me that they have a large number of formulations, custom formulations, for, say, semaglutide. They don't have that large number of formulations because they've just on their own decided to create those. They've got a large number of formulations in their formulary because prescribers have written for a large number of formulations. You can bet that a particular prescriber is not going to have 43 different formulations of zeppatide, but he or she may have four or five and write those four or five consistently. I don't think
34:16 Speaker 03 that sham personalization is absolutely patient-specific, and compounding pharmacies are, as they should be, filling those prescriptions.
34:27 Speaker 01 All right. So it does seem like there's a lot of nonsense being peddled out there. And a lot of it is technical enough that I can understand patients and even regulators or politicians getting confused. So it sounds like you've got your work cut out for you continuing to debunk this, this kind of stuff. And thank you both for coming here to help do that. I'm hoping that some of the listeners, they got at least a few aha moments about what's been going on. I think we've covered just about all the myths that these drug makers have been spreading. But some of them, there's some part of me that thinks there are a lot more of them out there and we're going to be seeing more of them in the future.
35:12 Speaker 01 I think I just saw a survey that said a big portion of Americans are wary of buying medication online. And that's got me wondering how much of that wariness is due to drug makers muddying the waters.
35:25 Speaker 03 It could be, but I don't want to completely throw drug makers under the bus on that count, Andrew. The National Association of Boards of Pharmacy says that it, as much as 90% of online pharmacies are bogus. That's scary, that there could be that many illicit entities out there. And so if you're going to purchase a drug, whether it's an FDA approved drug or a compounded drug, make sure you are working with a legitimate pharmacy. APC has on our website at compounding.com, a tool that we call, "Is It Legit?" And if you want to know if the pharmacy, purported pharmacy, that your drug comes from is legit or not, go to "Is It Legit?"
36:09 Speaker 03 and we provide a shortcut to your state and you can look up the name of the pharmacy there. If it's listed, generally speaking, it is a licensed pharmacy in that state and it is legit. If it's not listed, you may need to do a little more legwork and it could be that it is one of these bogus, bogus entities.
36:27 Speaker 01 And that's for both, you know, let's say I know a compounding pharmacy a few towns over, and it's also online pharmacies. I can look them both up?
36:36 Speaker 03 Yeah, online pharmacies, tele help platforms and online pharmacies have to be licensed. The pharmacy that is doing the fulfillment for the tele help platform has to be licensed. To Neil, did I get most of that right?
36:51 Speaker 04 Yeah.
36:52 Speaker 03 I have to look at Dr. Davis to make sure I'm correct.
36:54 Speaker 04 That's all right, but if the pharmacy or the quote unquote pharmacy you're looking to work with is not listed as licensed in the state where they would be shipping the medication, that they're not a legitimate state licensed pharmacy. They're one of these what NABP calls bogus online pharmacies. So best practice, don't use those. Only use legitimate state licensed compounding pharmacies for compounded medications or state licensed pharmacies for FDA approved medications.
37:22 Speaker 01 Okay, we'll put that in the show notes, but that was compounding.com is the site and the tool is called Is It Legit?
37:30 Speaker 03 Yeah, it's up at the top of the website. You'll see Is It Legit with a question mark and it'll take you right to the shortcut.
37:36 Speaker 01 Sounds great. All right. Thank you again, both for being here and doing that bit of myth busting. Before we play the end music, something I want to point out, if you are a compounding pharmacist or a technician or you prescribe compounding medications, APC is almost certainly helping you and helping your patients. I'm not going to go through everything we do, but I will say that APC is the biggest and in a good way, the loudest trade association for the whole compounding profession. So if you're not a member of APC, you really ought to be. We're working for you and we'd love to have you on board. Just head over to A4, that's the number four, PC.org. Check us out. All right. Now we can play
38:21 Speaker 01 that end music. Thanks for listening.
Previous Navigating Treatment of Dermatologic Inflammatory Conditions with Specialty Drug Therapies, with Vanderbilt Specialty Pharmacy, Vanderbilt Health | NASP Specialty Pharmacy Podcast Next MatchRX presents: Understanding DSCSA and the Road to 2026 | TWIRx Page updated November 14, 2026 · transcript and summary are machine-generated